1-(4-methyl-1,3-benzodioxol-5-yl)-2-aminopropane | 691876-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1-(4-methyl-1,3-benzodioxol-5-yl)-2-aminopropane
• 英文别名: 1-(4-methyl-1,3-benzodioxol-5-yl)propan-2-amine；3,4-Methylenedioxy-2-methyl-amphetamine；2-methyl-3,4-methylenedioxyamphetamine；2-Methyl-MDA
• CAS: 691876-73-0
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: WVACHJAKQMSYSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-methylpiperonal 在 乙酸铵 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 22.0h， 生成 1-(4-methyl-1,3-benzodioxol-5-yl)-2-aminopropane
  参考文献：
  名称：

  3,4-（亚甲二氧基）苯丙胺（MDA）的环甲基化衍生物的合成和药理评估。

  摘要：

  合成了著名的幻觉原和触觉原MDA（1a）的三种异构环甲基化衍生物，并评估了它们作为单胺释放剂和5-羟色胺激动剂的药理活性。发现2-甲基衍生物2a和5-甲基衍生物2b在抑制大鼠脑突触体制剂中的[3H] -5-羟色胺积聚方面比母体化合物更有效和更具选择性。在训练中可以从盐水中区分5-羟色胺释放剂和致幻剂的大鼠中证实了它们的体内活性。结果表明，化合物2a，b是已知的最有效的5-HT释放化合物，在寻找释放5-羟色胺而不抑制其吸收的抗抑郁药中，有望作为先导化合物使用。

  DOI：

  10.1021/jm9705925

文献信息

• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。
• COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS
  申请人：JENKINS Thomas E.

  公开号：US20120232066A1

  公开（公告）日：2012-09-13

  The present disclosure provides a composition comprising a GABA A agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested as a GI enzyme-cleavable prodrug with the first drug. Such an interaction can be additive or synergistic.

  本公开提供一种包含GABAA激动剂和GI酶抑制剂的组合物。本公开还提供一种包含（a）GI酶抑制剂和（b）第一药物的组合物，当第二药物以GI酶可切割的前药形式与第一药物共同摄入时，第一药物与第二药物相互作用产生不良效应。这种相互作用可以是加成的或协同的。
• METHODS OF SYNTHESIS AND PURIFICATION BY USE OF A SOLID SUPPORT
  申请人：Hammond Gerald B.

  公开号：US20110077393A1

  公开（公告）日：2011-03-31

  Disclosed herein are novel methods of using polymeric adsorbent resin for chemical synthesis and the purification of product therefrom. Also disclosed herein is a novel method of using silica gel for the combination of chemical reaction and chromatography into a single step. The methods disclosed herein increase the efficiency of chemical synthesis processes. Accordingly, the utility of the methods disclosed herein includes the ability to automate chemical synthesis and purification of the resulting products.

  本文披露了使用聚合物吸附树脂进行化学合成和从中纯化产品的新方法。本文还披露了一种使用硅胶将化学反应和色谱结合成单一步骤的新方法。本文所披露的方法提高了化学合成过程的效率。因此，本文所披露的方法的实用性包括自动化化学合成和纯化所得产品的能力。
• Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US20210030699A1

  公开（公告）日：2021-02-04

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及制备高纯度苯丙胺及苯丙胺类化合物的药物组合物，该组合物是通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的。本发明还涉及制备、传递和使用通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的苯丙胺类化合物的方法。